JPH02304027A - 前新生物性病変の全身的治療のための少なくとも１種のサイトカインを含む製剤組成物の使用 - Google Patents
前新生物性病変の全身的治療のための少なくとも１種のサイトカインを含む製剤組成物の使用Info
- Publication number
- JPH02304027A JPH02304027A JP2094884A JP9488490A JPH02304027A JP H02304027 A JPH02304027 A JP H02304027A JP 2094884 A JP2094884 A JP 2094884A JP 9488490 A JP9488490 A JP 9488490A JP H02304027 A JPH02304027 A JP H02304027A
- Authority
- JP
- Japan
- Prior art keywords
- cytokine
- cytokines
- pharmaceutical composition
- tnf
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 38
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 38
- 230000001855 preneoplastic effect Effects 0.000 title claims abstract description 20
- 230000003902 lesion Effects 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 21
- 230000009885 systemic effect Effects 0.000 claims abstract description 11
- 108010050904 Interferons Proteins 0.000 claims abstract description 7
- 102000014150 Interferons Human genes 0.000 claims abstract description 7
- 229940079322 interferon Drugs 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 230000002925 chemical effect Effects 0.000 claims description 3
- 230000000704 physical effect Effects 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 9
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract description 5
- 102000057041 human TNF Human genes 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000009117 preventive therapy Methods 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
- 238000009121 systemic therapy Methods 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 210000005170 neoplastic cell Anatomy 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000012270 DNA recombination Methods 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100437391 Mus musculus Bdp1 gene Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 201000002341 thymus lymphoma Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000002122 leukaemogenic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008017 ovarian lymphoma Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3911720 | 1989-04-11 | ||
| DE3911720.0 | 1989-04-11 | ||
| DE4005416 | 1990-02-21 | ||
| DE4005416.0 | 1990-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02304027A true JPH02304027A (ja) | 1990-12-17 |
Family
ID=25879777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2094884A Pending JPH02304027A (ja) | 1989-04-11 | 1990-04-10 | 前新生物性病変の全身的治療のための少なくとも１種のサイトカインを含む製剤組成物の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5128126A (enExample) |
| EP (1) | EP0392300B1 (enExample) |
| JP (1) | JPH02304027A (enExample) |
| KR (1) | KR900015754A (enExample) |
| AT (1) | ATE79763T1 (enExample) |
| AU (1) | AU638982B2 (enExample) |
| CA (1) | CA2014130A1 (enExample) |
| DE (1) | DE59000270D1 (enExample) |
| DK (1) | DK0392300T3 (enExample) |
| ES (1) | ES2034790T3 (enExample) |
| GR (1) | GR3005528T3 (enExample) |
| HU (1) | HU206834B (enExample) |
| IE (1) | IE64765B1 (enExample) |
| IL (1) | IL94052A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993011769A1 (fr) * | 1991-12-10 | 1993-06-24 | Otsuka Pharmaceutical Co., Ltd | Agent anticancereux |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5571797A (en) * | 1994-05-11 | 1996-11-05 | Arch Development Corporation | Method of inducing gene expression by ionizing radiation |
| WO1999040929A1 (en) * | 1998-02-12 | 1999-08-19 | The General Hospital Corporation | Methods to potentiate cancer therapies |
| US6719977B1 (en) * | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
| ES2529300T3 (es) | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
| US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
| US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050118138A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
| US20020150552A1 (en) * | 2000-09-12 | 2002-10-17 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20030129162A1 (en) * | 2000-09-12 | 2003-07-10 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20030082685A1 (en) * | 2001-04-06 | 2003-05-01 | WEICHSELBAUM Ralph R. | Chemotherapeutic induction of egr-1 promoter activity |
| US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
| US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
| WO2002097038A2 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2536041A1 (en) * | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
| EP1781284B1 (en) * | 2004-08-25 | 2010-10-13 | The University of Chicago | Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| US20080241100A1 (en) * | 2007-03-27 | 2008-10-02 | Stefan Strobl | Pharmaceutical composition comprising a cytokine |
| EP1977759A1 (en) * | 2007-03-27 | 2008-10-08 | 4Sc Ag | Pharmaceutical composition comprising a cytokine |
| JP2010522724A (ja) * | 2007-03-27 | 2010-07-08 | ４エスツェー アクチェンゲゼルシャフト | サイトカインを含有する医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983001198A1 (en) * | 1981-10-08 | 1983-04-14 | Kurt Frimann Berg | Method and composition for treating a patient suffering from interferon-susceptible disorder |
| AU9051882A (en) * | 1981-10-08 | 1983-04-27 | Berg, Kurt Frimann | Method and composition for treating a patient suffering from interferon-susceptible disorders |
| EP0077063B1 (en) * | 1981-10-13 | 1988-03-16 | Exovir, Inc. | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
| US4507281A (en) * | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| US4605555A (en) * | 1984-09-20 | 1986-08-12 | Sun Star Kabushiki Kaisha | Composition and method for treating keratosic disorder of skin and mucosa |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
-
1990
- 1990-03-31 ES ES199090106221T patent/ES2034790T3/es not_active Expired - Lifetime
- 1990-03-31 EP EP90106221A patent/EP0392300B1/de not_active Expired - Lifetime
- 1990-03-31 DK DK90106221.6T patent/DK0392300T3/da active
- 1990-03-31 DE DE9090106221T patent/DE59000270D1/de not_active Expired - Fee Related
- 1990-03-31 AT AT90106221T patent/ATE79763T1/de not_active IP Right Cessation
- 1990-04-09 CA CA002014130A patent/CA2014130A1/en not_active Abandoned
- 1990-04-09 IL IL9405290A patent/IL94052A/en not_active IP Right Cessation
- 1990-04-09 US US07/505,269 patent/US5128126A/en not_active Expired - Fee Related
- 1990-04-10 IE IE129790A patent/IE64765B1/en not_active IP Right Cessation
- 1990-04-10 JP JP2094884A patent/JPH02304027A/ja active Pending
- 1990-04-10 HU HU902145A patent/HU206834B/hu not_active IP Right Cessation
- 1990-04-10 AU AU53105/90A patent/AU638982B2/en not_active Ceased
- 1990-04-11 KR KR1019900004955A patent/KR900015754A/ko not_active Ceased
-
1992
- 1992-08-27 GR GR920401805T patent/GR3005528T3/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993011769A1 (fr) * | 1991-12-10 | 1993-06-24 | Otsuka Pharmaceutical Co., Ltd | Agent anticancereux |
Also Published As
| Publication number | Publication date |
|---|---|
| IL94052A0 (en) | 1991-01-31 |
| CA2014130A1 (en) | 1990-10-11 |
| EP0392300A1 (de) | 1990-10-17 |
| HU902145D0 (en) | 1990-07-28 |
| EP0392300B1 (de) | 1992-08-26 |
| HUT54303A (en) | 1991-02-28 |
| ATE79763T1 (de) | 1992-09-15 |
| AU638982B2 (en) | 1993-07-15 |
| AU5310590A (en) | 1990-10-18 |
| IE901297L (en) | 1990-10-11 |
| KR900015754A (ko) | 1990-11-10 |
| US5128126A (en) | 1992-07-07 |
| DK0392300T3 (da) | 1992-09-28 |
| GR3005528T3 (enExample) | 1993-06-07 |
| HU206834B (en) | 1993-01-28 |
| IL94052A (en) | 1995-06-29 |
| ES2034790T3 (es) | 1993-04-01 |
| DE59000270D1 (de) | 1992-10-01 |
| IE64765B1 (en) | 1995-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH02304027A (ja) | 前新生物性病変の全身的治療のための少なくとも１種のサイトカインを含む製剤組成物の使用 | |
| DE69330032T2 (de) | Therapeutisches kombinationspräparat enthaltend interferon | |
| DE69632062T2 (de) | Kontinuierliche, niedrigdosierte zytokine-infusionstherapie | |
| US4791101A (en) | Synergistic mixtures of interferons and tumor necrosis factor | |
| DE69333321T2 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| Edwards et al. | Effect of intralesional a2-interferon on actinic keratoses | |
| KR960008009B1 (ko) | 인터류킨 및 이중-가닥 rna를 포함하는 상승작용화 조성물 | |
| JP2846629B2 (ja) | 組換えコロニー刺激因子−１を含んで成る医薬組成物 | |
| EP0225759B1 (en) | Interferon compositions | |
| DE69832902T2 (de) | Oromukosal-zytokin-zusammensetzungen und ihre verwendung | |
| US5725850A (en) | Use of CSF-1 to treat tumor burden | |
| Harning et al. | A treatment for metastasis of murine ocular melanoma. | |
| EP0955056A1 (en) | Recombinant colony stimulating factor-1 for treatment of fungal infection | |
| WO2004022088A1 (en) | Interferon and immunoglobulin fc fragment hybrid | |
| Brzoska et al. | Immunomodulating effects of interferons: conclusions for therapy | |
| Mazuski et al. | Effects of cytokine antagonists on the hepatic acute-phase response | |
| KR0169975B1 (ko) | 감마 인터페론 활성을 갖는 폴리펩티드를 함유하는 원발성 흉막암 치료용 제약 조성물 | |
| Reiter et al. | 183. Possible roles for interferon-α in remission of AIDS-related Kaposi's sarcoma | |
| Ross et al. | 184. All trans-retinoic acid inhibits the growth of human lung cancer cells and alter cytokine production | |
| KOREN et al. | Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2 | |
| JPH04360840A (ja) | 血小板減少症治療剤 | |
| EP0205629A1 (de) | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen | |
| Richtsmeier | The interferons | |
| JPH01501862A (ja) | インタ−フェロン及び放射線療法による癌の治療 | |
| JPH0354925B2 (enExample) |